Thus, targeting more recently identified immune checkpoints such as CD137 and CD47, alone or in combination with other therapeutic approaches to enhance their efficacy, could be of therapeutic value in the treatment of tumors such as GBM. Here, TNFRSF9 is linked to glioblastoma.